» Articles » PMID: 1682684

Prevention of Travellers' Diarrhoea by Oral B-subunit/whole-cell Cholera Vaccine

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1991 Nov 23
PMID 1682684
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

B-subunit/whole-cell cholera vaccine (BS-WC) has been shown to give Bangladeshi mothers and children only 3 months' protection against severe diarrhoea due to enterotoxigenic Escherichia coli (ETEC). Since a long-lasting effect is not necessary for protection against travellers' diarrhoea, a prospective double-blind study was conducted among tourists who went to Morocco from Finland. 307 tourists received two oral doses of BS-WC, whereas 308 controls received a placebo before departure. A research team went out with tourists and a laboratory for enteric pathogens was set up on location. A faecal specimen was taken from 100 randomly selected subjects before departure, from all travellers with diarrhoea, and routinely after return. Enteropathogenic bacteria were not isolated from any of the pre-departure specimens but were present during or after the holiday in 47% of tourists with travellers' diarrhoea, and in 14% of those without diarrhoea. BS-WC induced a 52% protection (p = 0.013) against diarrhoea caused by ETEC. The protection was better for mixed infections (65%, p = 0.016). The protective efficacy against a combination of ETEC and any other pathogen was 71% (p = 0.02), and that against ETEC plus Salmonella enterica even better at 82% (p = 0.01). Partial protection against travellers' diarrhoea is thus obtainable by active immunisation with BS-WC.

Citing Articles

Targeting Enterotoxins: Advancing Vaccine Development for Enterotoxigenic ETEC.

Salvador-Erro J, Pastor Y, Gamazo C Toxins (Basel). 2025; 17(2).

PMID: 39998088 PMC: 11860656. DOI: 10.3390/toxins17020071.


Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally.

Pasetti M, Milletich P, White J, Butts J, Brady R, Dickey M NPJ Vaccines. 2025; 10(1):23.

PMID: 39893179 PMC: 11787345. DOI: 10.1038/s41541-025-01071-7.


Bismuth subsalicylate, probiotics, rifaximin and vaccines for the prevention of travelers' diarrhea: a systematic review and network meta-analysis.

Fan H, Liu I, Gao L, Wu L Front Pharmacol. 2024; 15:1361501.

PMID: 38698820 PMC: 11063717. DOI: 10.3389/fphar.2024.1361501.


Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701).

Talaat K, Porter C, Chakraborty S, Feijoo B, Brubaker J, Adjoodani B Microorganisms. 2024; 12(4).

PMID: 38674674 PMC: 11051778. DOI: 10.3390/microorganisms12040727.


A Perspective on the Strategy for Advancing ETVAX, An Anti-ETEC Diarrheal Disease Vaccine, into a Field Efficacy Trial in Gambian Children: Rationale, Challenges, Lessons Learned, and Future Directions.

Hossain M, Svennerholm A, Carlin N, DAlessandro U, Wierzba T Microorganisms. 2024; 12(1).

PMID: 38257916 PMC: 10819518. DOI: 10.3390/microorganisms12010090.